Do analysts recommend BHC or APHA?

Given Aphria's higher probable upside, analysts clearly believe Aphria is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aphria 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, BHC or APHA?

Bausch Health Companies has higher revenue and earnings than Aphria. Bausch Health Companies is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch Health Companies C$10.53B 0.25 -C$125.65M -C$3.24 N/A Aphria C$611.06M 0.00 -C$637.39M -C$2.01 N/A

Do analysts rate PBH or BHC?

Premium Brands currently has a consensus price target of C$118.62, indicating a potential upside of 39.17%. Given Premium Brands' stronger consensus rating and higher possible upside, equities analysts plainly believe Premium Brands is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Premium Brands 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate AUP or BHC?

Given Aurinia Pharmaceuticals' higher possible upside, equities analysts clearly believe Aurinia Pharmaceuticals is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend BHC or SLS?

Solaris Resources has a consensus price target of C$19.50, suggesting a potential upside of 57.77%. Given Solaris Resources' stronger consensus rating and higher probable upside, analysts plainly believe Solaris Resources is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Solaris Resources 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend BHC or CARA?

Given Cara Operations' higher probable upside, analysts plainly believe Cara Operations is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, BHC or CARA?

Cara Operations has lower revenue, but higher earnings than Bausch Health Companies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bausch Health Companies C$10.53B 0.25 -C$125.65M -C$3.24 N/A Cara Operations N/A N/A N/A N/A N/A

Bausch Health Companies (BHC) Competitors

C$6.96 0.00 (0.00%)

As of 07/3/2026 04:00 PM Eastern

Compare

BHC vs. APHA, PBH, AUP, SLS, and CARA

Should you buy Bausch Health Companies stock or one of its competitors? MarketBeat compares Bausch Health Companies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch Health Companies include Aphria (APHA), Premium Brands (PBH), Aurinia Pharmaceuticals (AUP), Solaris Resources (SLS), and Cara Operations (CARA). These companies are all part of the "pharmaceutical products" industry.

How does Bausch Health Companies compare to Aphria?

Bausch Health Companies (TSE:BHC) and Aphria (TSE:APHA) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Aphria has a net margin of 0.00% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Aphria's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-13.54%	120.43%	4.16%
Aphria	N/A	N/A	N/A

Given Aphria's higher probable upside, analysts clearly believe Aphria is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aphria	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bausch Health Companies has higher revenue and earnings than Aphria. Bausch Health Companies is trading at a lower price-to-earnings ratio than Aphria, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.53B	0.25	-C$125.65M	-C$3.24	N/A
Aphria	C$611.06M	0.00	-C$637.39M	-C$2.01	N/A

11.3% of Bausch Health Companies shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bausch Health Companies' average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company	Overall Sentiment
Bausch Health Companies	Neutral
Aphria	Neutral

Summary

Bausch Health Companies beats Aphria on 8 of the 11 factors compared between the two stocks.

How does Bausch Health Companies compare to Premium Brands?

Premium Brands (TSE:PBH) and Bausch Health Companies (TSE:BHC) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Premium Brands had 4 more articles in the media than Bausch Health Companies. MarketBeat recorded 4 mentions for Premium Brands and 0 mentions for Bausch Health Companies. Premium Brands' average media sentiment score of 0.19 beat Bausch Health Companies' score of 0.00 indicating that Premium Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Premium Brands	Neutral
Bausch Health Companies	Neutral

Premium Brands has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Premium Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Premium Brands	C$7.88B	0.56	C$99.56M	C$0.90	94.70
Bausch Health Companies	C$10.53B	0.25	-C$125.65M	-C$3.24	N/A

Premium Brands has a net margin of 0.52% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Premium Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Premium Brands	0.52%	2.21%	3.61%
Bausch Health Companies	-13.54%	120.43%	4.16%

Premium Brands currently has a consensus price target of C$118.62, indicating a potential upside of 39.17%. Given Premium Brands' stronger consensus rating and higher possible upside, equities analysts plainly believe Premium Brands is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Premium Brands	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Premium Brands has a beta of 0.88205, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.942978, suggesting that its stock price is 6% less volatile than the broader market.

32.9% of Premium Brands shares are held by institutional investors. Comparatively, 11.3% of Bausch Health Companies shares are held by institutional investors. 2.0% of Premium Brands shares are held by insiders. Comparatively, 11.3% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Premium Brands beats Bausch Health Companies on 11 of the 16 factors compared between the two stocks.

How does Bausch Health Companies compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (TSE:AUP) and Bausch Health Companies (TSE:BHC) are both mid-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, Aurinia Pharmaceuticals' average media sentiment score of 0.00 equaled Bausch Health Companies'average media sentiment score.

Company	Overall Sentiment
Aurinia Pharmaceuticals	Neutral
Bausch Health Companies	Neutral

Aurinia Pharmaceuticals has a net margin of 0.00% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	N/A	N/A	N/A
Bausch Health Companies	-13.54%	120.43%	4.16%

Given Aurinia Pharmaceuticals' higher possible upside, equities analysts clearly believe Aurinia Pharmaceuticals is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.3% of Bausch Health Companies shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bausch Health Companies has higher revenue and earnings than Aurinia Pharmaceuticals. Bausch Health Companies is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	C$57.59M	0.00	-C$190.03M	-C$1.48	N/A
Bausch Health Companies	C$10.53B	0.25	-C$125.65M	-C$3.24	N/A

Summary

Bausch Health Companies beats Aurinia Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Bausch Health Companies compare to Solaris Resources?

Bausch Health Companies (TSE:BHC) and Solaris Resources (TSE:SLS) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

In the previous week, Solaris Resources had 1 more articles in the media than Bausch Health Companies. MarketBeat recorded 1 mentions for Solaris Resources and 0 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 0.00 equaled Solaris Resources'average media sentiment score.

Company	Overall Sentiment
Bausch Health Companies	Neutral
Solaris Resources	Neutral

Bausch Health Companies has a beta of 0.942978, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Solaris Resources has a beta of 1.721408, meaning that its stock price is 72% more volatile than the broader market.

Solaris Resources has lower revenue, but higher earnings than Bausch Health Companies. Solaris Resources is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.53B	0.25	-C$125.65M	-C$3.24	N/A
Solaris Resources	N/A	N/A	-C$46.49M	-C$0.19	N/A

Solaris Resources has a net margin of 0.00% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Solaris Resources' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-13.54%	120.43%	4.16%
Solaris Resources	N/A	60.97%	-51.67%

11.3% of Bausch Health Companies shares are held by institutional investors. Comparatively, 16.4% of Solaris Resources shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by insiders. Comparatively, 40.6% of Solaris Resources shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Solaris Resources has a consensus price target of C$19.50, suggesting a potential upside of 57.77%. Given Solaris Resources' stronger consensus rating and higher probable upside, analysts plainly believe Solaris Resources is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Solaris Resources	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Solaris Resources beats Bausch Health Companies on 10 of the 14 factors compared between the two stocks.

How does Bausch Health Companies compare to Cara Operations?

Bausch Health Companies (TSE:BHC) and Cara Operations (TSE:CARA) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Bausch Health Companies' average media sentiment score of 0.00 equaled Cara Operations'average media sentiment score.

Company	Overall Sentiment
Bausch Health Companies	Neutral
Cara Operations	Neutral

Given Cara Operations' higher probable upside, analysts plainly believe Cara Operations is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cara Operations has a net margin of 0.00% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Cara Operations' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-13.54%	120.43%	4.16%
Cara Operations	N/A	N/A	N/A

Cara Operations has lower revenue, but higher earnings than Bausch Health Companies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	C$10.53B	0.25	-C$125.65M	-C$3.24	N/A
Cara Operations	N/A	N/A	N/A	N/A	N/A

11.3% of Bausch Health Companies shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Bausch Health Companies beats Cara Operations on 6 of the 8 factors compared between the two stocks.

Get Bausch Health Companies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHC vs. The Competition

Export

Metric	Bausch Health Companies	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$2.60B	C$6.60B	C$7.18B	C$13.07B
Dividend Yield	0.76%	2.83%	2.67%	6.18%
P/E Ratio	-2.15	5.11	28.02	36.51
Price / Sales	0.25	1,653.39	532.59	10.34
Price / Cash	7.76	10.18	49.26	82.29
Price / Book	-2.38	10.83	10.96	4.52
Net Income	-C$125.65M	C$20.27B	C$3.57B	C$299.09M
7 Day Performance	2.81%	1.30%	2.12%	1.85%
1 Month Performance	-7.08%	-1.17%	5.25%	1.71%
1 Year Performance	-25.88%	9.82%	33.29%	36.40%

Bausch Health Companies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHC Bausch Health Companies	0.2601 of 5 stars	C$6.96 flat	N/A	-25.9%	C$2.60B	C$10.53B	N/A	19,900
APHA Aphria	N/A	N/A	N/A	N/A	C$5.24B	C$611.06M	N/A	1,200
PBH Premium Brands	3.6774 of 5 stars	C$85.36 +1.5%	C$118.62 +39.0%	+1.7%	C$4.44B	C$7.88B	94.84	540	News Coverage
AUP Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	C$2.15B	C$57.59M	N/A	300	High Trading Volume
SLS Solaris Resources	1.373 of 5 stars	C$11.22 -7.1%	C$19.50 +73.8%	+64.1%	C$1.87B	N/A	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:BHC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Companies (BHC) Competitors

BHC vs. APHA, PBH, AUP, SLS, and CARA

How does Bausch Health Companies compare to Aphria?

Summary

How does Bausch Health Companies compare to Premium Brands?

Summary

How does Bausch Health Companies compare to Aurinia Pharmaceuticals?

Summary

How does Bausch Health Companies compare to Solaris Resources?

Summary

How does Bausch Health Companies compare to Cara Operations?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Companies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Companies (BHC) Competitors

BHC vs. APHA, PBH, AUP, SLS, and CARA

How does Bausch Health Companies compare to Aphria?

Is BHC or APHA more profitable?

Do analysts recommend BHC or APHA?

Which has stronger earnings and valuation, BHC or APHA?

Do insiders & institutionals have more ownership in BHC or APHA?

Does the media prefer BHC or APHA?

Summary

How does Bausch Health Companies compare to Premium Brands?

Does the media prefer PBH or BHC?

Which has stronger valuation & earnings, PBH or BHC?

Is PBH or BHC more profitable?

Do analysts rate PBH or BHC?

Which has more risk & volatility, PBH or BHC?

Do institutionals & insiders believe in PBH or BHC?

Summary

How does Bausch Health Companies compare to Aurinia Pharmaceuticals?

Does the media prefer AUP or BHC?

Is AUP or BHC more profitable?

Do analysts rate AUP or BHC?

Do institutionals and insiders believe in AUP or BHC?

Which has better earnings and valuation, AUP or BHC?

Summary

How does Bausch Health Companies compare to Solaris Resources?

Does the media favor BHC or SLS?

Which has more volatility & risk, BHC or SLS?

Which has stronger valuation and earnings, BHC or SLS?

Is BHC or SLS more profitable?

Do institutionals and insiders hold more shares of BHC or SLS?

Do analysts recommend BHC or SLS?

Summary

How does Bausch Health Companies compare to Cara Operations?

Does the media favor BHC or CARA?

Do analysts recommend BHC or CARA?

Is BHC or CARA more profitable?

Which has better valuation and earnings, BHC or CARA?

Do institutionals & insiders believe in BHC or CARA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Companies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools